Fundraising FoxLumina Pharmaceuticals
Boston, US · Founded 2025 · Delaware corporation
Find your way into Lumina Pharmaceuticals
Sign up to see every warm intro you have to Lumina Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lumina Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lumina Pharmaceuticals is a clinical-stage company that develops diagnostic and therapeutic radiopharmaceuticals using peptide technology.
Founders & leadership
CF
Cara FerreiraChief Executive OfficerCara Ferreira spent seven years in strategy consulting at McKinsey and over a decade leading in the medical isotope and radiopharmaceutical industry, with a PhD in science.
AG
Alma Gregory SorensenNamed on SEC filing
Board
PC
Peter CaravanBoard director
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2025
▶$2MraisedJun 2025 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJun 2025 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Alma Gregory SorensenExecutive Officer, Director
- Peter CaravanDirector
- Cara FerreiraExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $25K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Lumos PharmaLumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency. It also pursues partnerships to in-license or acquire additional rare disease therapeutic candidates for development and commercialization.
IllumentxIllumen Therapeutics is a biotech company developing first-in-class PARN inhibitor drugs that increase functional p53, a tumor suppressor, as a treatment for aggressive cancers. Its drug development focuses on targeting p53 dysregulation to improve cancer patient survival.
LumenLumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics. The company serves biopharma customers seeking alternatives to traditional drug manufacturing.
Lantern PharmaLantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.
Neumora TherapeuticsNeumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
Companies working in the same space as Lumina Pharmaceuticals.
Frequently asked questions
- What does Lumina Pharmaceuticals do?
- Lumina Pharmaceuticals is a clinical-stage company that develops diagnostic and therapeutic radiopharmaceuticals using peptide technology.
- How much funding has Lumina Pharmaceuticals raised?
- Lumina Pharmaceuticals has disclosed $2M raised across 1 round.
- Where is Lumina Pharmaceuticals headquartered?
- Lumina Pharmaceuticals is headquartered in Boston, US.